Cephalon completes acquisition of Mepha

FRAZER, Pa. Cephalon has completed its acquisition of Swiss drug maker Mepha, Cephalon announced Friday.

The $615.4 million acquisition makes Mepha a wholly owned subsidiary of Cephalon.

“We are proud to include Mepha as part of the Cephalon family,” Cephalon chairman and CEO Frank Baldino said. “Mepha has a strong reputation for high-quality products and services that deliver value to patients and healthcare professionals.”